AFAP1L2 and prostate carcinoma: Kaplan–Meier analysis (Figure 1B) revealed that patients with highly expressed XB130 have significantly decreased survival rate than those with lower XB130 expression (p = 0.0121), which indicated that XB130 expression was inversely correlated with survival in prostate cancer.